Losartan Potassium we care Special Precautions

Patients with volume-depletion (e.g. those treated with high-dose diuretics) may experience hypotension, which may be minimised by initiating treatment with a low dose of Losartan Potassium. Halving of the dose should be considered for patients with a history of hepatic impairment (see Dosage & Administration).
Since hyperkalemia may occur, serum-potassium concentrations should be monitored, especially in the elderly and patients with renal impairment and the concomitant use of potassium-sparing diuretics should generally be avoided (see Interactions).
When impaired renal function is present, changes in renal function as a consequence of inhibiting the renin-angiotensin system including renal failure have been reported in susceptible individuals. These changes in renal function may be reversible upon discontinuation of Losartan Potassium therapy, in some patients.
In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotemia and (less frequently) with acute renal failure and/or death. Similar outcomes are likely with Losartan Potassium therapy.
Agents affecting the renin-angiotensin system may increase blood urea and serum creatinine in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney. These changes in renal function may be reversible upon discontinuation of Losartan Potassium therapy.